New appointment at Généthon
This article was originally published in Scrip
Dr Frédéric Revah has been appointed chief executive of Généthon, the not-for-profit biotherapy research centre created by the French Muscular Dystrophy Association (AFM) and funded with donations from the country's annual Telethon. Dr Revah has more than 20 years' experience in the pharmaceutical and biotech industries and in academic research, with particular expertise in the management of therapeutic innovation. Most recently he was CEO of the oncology start-up Sepal Pharma.
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.